2nd Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$1,590,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
STEPHANIE A. DYSON —
JEFFREY LAST New LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4385 (117th), H.R. 1319 (117th), H.R. 7667 (117th)

Medicare/Medicaid MMM

Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues

LobbyistCovered position, as disclosed
JOHN DEOUDES —
STEPHANIE A. DYSON —
JEFFREY LAST New LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (117th), H.R. 19 (117th), H.R. 5237 (117th)

Trade (domestic/foreign) TRD

Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill

LobbyistCovered position, as disclosed
JOHN DEOUDES —
JEFFREY LAST New LA,Senator Cornyn 11/17-4/22; Health Policy Advisor, Rep.Brady 1/17-11/17; LA, Rep. Lance 1/09-11/12; LC, Rep. Knollenberg 1/06-12/08
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 4521 (117th)

Taxation/Internal Revenue Code TAX

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions.

LobbyistCovered position, as disclosed
JOHN DEOUDES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.